OS FLT3-ITD⁻/FLT3i⁻ was assessed, given the known frequent cooccurrence of FLT3-ITD mutations in NPM1⁺AML and the emerging data demonstrating improved OS in patients receiving an FLT3i. (A) No difference in OS was seen in patients of all ages treated with HMA + VEN vs IC (median OS, NR vs 5.7 years; P = .303). (B) In patients age >65 years, HMA + VEN continued to demonstrate improved OS compared with IC (median OS, NR vs 0.9 years; P = .008). In both age groups, HMA + VEN and IC significantly outperformed HMA monotherapy (median OS, 0.5 years).